Yichen Yang

Yichen Yang

Auto-generated profile, based on publicly available information

Yichen Yang

Tianjin Cancer Institute, Tianjin Key Laboratory of Digestive Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
FTFei Tian
Fei Tian
DLDong Liu
Dong Liu
NWNa Wei
Na Wei
QFQianqian Fu
Qianqian Fu
LSLin Sun
Lin Sun
XLXiangchun Li
Xiangchun Li
Cancer of unknown primary (CUP) site poses diagnostic challenges due to its elusive nature. Many cases of CUP manifest as pleural and peritoneal serous effusions. Leveraging cytological images from 57,220 cases at four tertiary hospitals, we developed a deep-learning method for tumor origin differentiation using cytological histology (TORCH) that can identify malignancy and predict tumor origin in both hydrothorax and ascites. We examined its performance on three internal (n = 12,799) and two external (n = 14,538) testing sets. In both internal and external testing sets, TORCH achieved area under the receiver operating curve values ranging from 0.953 to 0.991 for cancer diagnosis and 0.953 to 0.979 for tumor origin localization. TORCH accurately predicted primary tumor origins, with a top-1 accuracy of 82.6% and top-3 accuracy of 98.9%. Compared with results derived from pathologists, TORCH showed better prediction efficacy (1.677 versus 1.265, P < 0.001), enhancing junior pathologists’ diagnostic scores significantly (1.326 versus 1.101, P < 0.001). Patients with CUP whose initial treatment protocol was concordant with TORCH-predicted origins had better overall survival than those who were administrated discordant treatment (27 versus 17 months, P = 0.006). Our study underscores the potential of TORCH as a valuable ancillary tool in clinical practice, although further validation in randomized trials is warranted.

1 December 2017 in Methods
Verified
Journal Article
Closed access
YHYing Hu
Ying Hu
YYYichen Yang
Yichen Yang
ZFZhonghai Fang
Zhonghai Fang
YHYanshi Hu
Yanshi Hu
LZLei Zhang
Lei Zhang
JWJu Wang
Ju Wang

4 March 2025 in Cancer Research
Verified
Journal Article
Closed access
MWMeixi Wang
Meixi Wang
FZFangdi Zou
Fangdi Zou
SWShengxin Wang
Shengxin Wang
YYYichen Yang
Yichen Yang
CXCong Xia
Cong Xia
ZMZeyun Mi
Zeyun Mi
As the third most common cause of cancer-related mortality, hepatocellular carcinoma (HCC) is a global health concern. Despite its prevalence, treatment options are limited, underscoring the need to identify potential therapeutic targets and strategies. In this study, we identified amplification of cAMP response element-binding protein–regulated transcription coactivator 2 (CRTC2), situated in the 1q21.3 region, due to copy-number alterations in HCC. In a cohort of patients with HCC, CRTC2 protein levels were frequently elevated and correlated with poor prognosis. Genetic deletion of Crtc2 significantly impeded the onset and progression of HCC in mouse models. CRTC2 formed cytoplasmic condensates that recruited the N6-methyladenosine (m6A) reader YTHDF2. Furthermore, CRTC2 promoted the translocation of m6A-modified mRNAs from decay sites to polyribosomes by interacting with PABP1. The activities of CRTC2 counteracted YTHDF2-mediated mRNA degradation to enhance the translational efficiency of specific mRNAs, including those encoding LRP5 and c-Jun. Targeting Crtc2 in hepatocytes using AAV8.sgCrtc2 elicited substantial therapeutic benefits in HCC mouse models and significantly enhanced the sensitivity to lenvatinib. Together, this research elucidates the pivotal role and underlying molecular mechanisms of CRTC2 in hepatocarcinogenesis and lenvatinib resistance, highlighting its potential clinical and therapeutic applications. Significance: CRTC2 hijacks the YTHDF2–m6A pathway to increase translation of c-Jun and promote hepatocellular carcinoma development and lenvatinib resistance, indicating that CRTC2 is a promising biomarker and therapeutic target.

22 October 2021
Verified
Conference Paper
Open access
YYYichen Yang
Yichen Yang
WWWei Wei
Wei Wei
Deng ChenDeng Chen
Deng Chen
Industrial robot pose estimation has important applications in industrial robot safety detection and abnormal pose analysis. Aiming at the current problems of low accuracy of industrial robot pose estimation, this paper proposes a pose estimation method of six-axis industrial robots based on deep learning. Firstly, this paper uses the object detection method to detect the six joint axes of the industrial robot, and then the detected results are converted into the pose of the industrial robot. Additionally, this paper constructs an image dataset for industrial robot pose. Our method lays the foundation for industrial robot safety detection and abnormal pose analysis. The experimental results on the self-constructed dataset show that our method can accurately estimate the pose of the industrial robot, and the mean average precision (mAP) is 82.98%. It also outperforms previous industrial robot pose estimation methods by a significant margin of 29.98% performance gain.

2 June 2025
Verified
Other
Open access
MWMeixi Wang
Meixi Wang
FZFangdi Zou
Fangdi Zou
SWShengxin Wang
Shengxin Wang
YYYichen Yang
Yichen Yang
CXCong Xia
Cong Xia
ZMZeyun Mi
Zeyun Mi
As the third most common cause of cancer-related mortality, hepatocellular carcinoma (HCC) is a global health concern. Despite its prevalence, treatment options are limited, underscoring the need to identify potential therapeutic targets and strategies. In this study, we identified amplification of cAMP response element-binding protein–regulated transcription coactivator 2 (CRTC2), situated in the 1q21.3 region, due to copy-number alterations in HCC. In a cohort of patients with HCC, CRTC2 protein levels were frequently elevated and correlated with poor prognosis. Genetic deletion of Crtc2 significantly impeded the onset and progression of HCC in mouse models. CRTC2 formed cytoplasmic condensates that recruited the N6-methyladenosine (m6A) reader YTHDF2. Furthermore, CRTC2 promoted the translocation of m6A-modified mRNAs from decay sites to polyribosomes by interacting with PABP1. The activities of CRTC2 counteracted YTHDF2-mediated mRNA degradation to enhance the translational efficiency of specific mRNAs, including those encoding LRP5 and c-Jun. Targeting Crtc2 in hepatocytes using AAV8.sgCrtc2 elicited substantial therapeutic benefits in HCC mouse models and significantly enhanced the sensitivity to lenvatinib. Together, this research elucidates the pivotal role and underlying molecular mechanisms of CRTC2 in hepatocarcinogenesis and lenvatinib resistance, highlighting its potential clinical and therapeutic applications.Significance: CRTC2 hijacks the YTHDF2–m6A pathway to increase translation of c-Jun and promote hepatocellular carcinoma development and lenvatinib resistance, indicating that CRTC2 is a promising biomarker and therapeutic target.